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REVIEW
Morning symptoms in COPD: a treatable yet often overlooked factor
Amanda R. van Buula, Marise J. Kasteleyna, Niels H. Chavannesb and Christian Taubea
aDepartment of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands; bDepartment of Public Health and Primary Care, Leiden
University Medical Center, Leiden, The Netherlands
ABSTRACT
Introduction: Chronic obstructive pulmonary disease (COPD) patients experience the morning as the
worst period of the day. Nevertheless, morning symptoms are not mentioned in COPD guidelines.
Areas covered: Different topics on morning symptoms are covered in this review to underline their
importance: occurrence, tools for assessment and therapies to limit morning symptoms.
Expert commentary: Morning symptoms are common and have a negative influence on a patient’s life.
Pharmacotherapy seems to be effective in decreasing morning symptoms. A validated tool to assess
morning symptoms is lacking. Therefore, more research should focus on assessing morning symptoms
with a validated tool to further prove the effect of (pharmaco-) therapy. This will hopefully result in
inclusion of morning symptoms in future guidelines.
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Chronic obstructive pulmonary disease (COPD) is a common
lung disease worldwide [1]. This chronic lung disease is char-
acterized by chronic inflammation of the airways that result in
irreversible and progressive airflow limitation [2]. COPD has
great impact on a patient’s life and is associated with a lower
quality of life [3], lower physical activity [4], disabilities [5], and
mortality [6]. Most common symptoms in COPD are dyspnea,
cough, sputum production, wheezing, and chest tightness [7].
In the newest Global Initiative for Chronic Obstructive Lung
Disease (GOLD) statements, symptoms also have a place in the
gradation of the severity of COPD [7].
COPD symptoms differ day-by-day and symptoms may occur
during any part of the day [8,9]. In recent years, it has become
more clear that COPD patients experience the morning as the
worst period of the day [10]. However, exact prevalence rates are
unknown. Prevalence rates shown in current literature are
derived from different questionnaires since a validated morning
symptom questionnaire is lacking. Moreover, no consistent defi-
nition for the morning is used. Morning symptoms are not men-
tioned in international COPD guidelines and statements yet [7].
In contrast, asthma guidelines recommend physicians to ask
asthma patients about morning symptoms [11]. Moreover, one
statement recommends using morning symptoms as a tool to
differentiate between asthma and COPD, where the presence of
morning symptoms is an indicator for asthma [7]. Consequently,
physicians do not routinely discuss morning symptoms with
their COPD patients; morning symptoms are not usually targeted
as a goal for therapy. Furthermore, in (medication) studies,
researchers barely focus on morning symptoms and head-to-
head comparisons between treatment options are scarce.
Nevertheless, patients reported a need for discussing morning
symptoms and they expect of prescribed medication that it will
improve their ability to perform morning activities [12].
Therefore, there is need for more detailed assessment of morn-
ing symptoms not only in COPD in practice but also in research.
Based on this statement, it is important to gather the current
evidence of morning symptoms in COPD and underline this
overlooked factor. The aim of this review is to critically assess
the evidence of morning symptoms in COPD, with special focus
on occurrence, the available morning symptom questionnaires,
and current therapies. In the process of evaluating the current
findings on this topic, gaps in our understanding and knowledge
about morning symptom will become obvious. Defining these
gaps can help to assess areas needing further research and could
result in novel approaches to assess and treat mornings symp-
toms. This will probably lead to an inclusion of this topic in
international guidelines in the future. This fits well into more
modern approaches to use patient-reported outcomes in addi-
tion to traditional parameters as pulmonary function in the
assessment of COPD patients.
2. Occurrence of morning symptoms and associated
factors
It has been shown that the morning is the most troublesome
period for COPD patients [3]. It is not well known why symp-
toms vary over the course of the day in COPD patients.
Possibly, they suffer from morning symptoms since the
morning is the most active part of the day including many
activities of daily living such as washing and dressing. These
activities can trigger morning symptoms [13]. Another sug-
gestion is that it can be due to circadian variation in pul-
monary function [14]. However, this change in pulmonary
function does not directly translate into a difference in
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exercise capacity especially when assessing peak exercise
capacity [15]. Interestingly, half of patients showed a diurnal
change in peak exercise capacity independent of changes in
pulmonary function [15]. The greatest exercise capacity was
reached in the afternoon. In conclusion, the effects of circa-
dian variation on morning symptoms are unclear and further
research is warranted. At this moment, there is not a vali-
dated universal tool available to assess morning symptoms.
Subsequently, in previous studies, the occurrence of morning
symptoms was assessed with different tools. The studies
showed that a substantial part of the COPD population suffer
from morning symptoms with rates between 39.8% and
94.4% [12,16–24] (Figure 1). In some studies, the percentage
of patients with morning symptoms is probably underesti-
mated and in other studies probably overestimated. There
are multiple factors that could influence the incidence rates.
One possibility for differences between studies could be the
usage of different definitions for the morning period. If the
morning was defined as only the moment of waking up,
patients who have problems with performing routine activ-
ities during the rest of the morning were missed, resulting in
an underestimation of morning symptoms. A different reason
could be that most of the time patients who were included in
the studies were already being treated in clinical practices.
These patients have probably already attended a health-care
provider because of their symptoms and therefore, these
studies might be biased toward more symptomatic patients.
This bias would result in an overestimation of morning symp-
toms in the total COPD population. A third issue could be
that patients underestimate their symptoms: 36% of patients
who describe their symptoms as being mild to moderate are
too breathless to leave the house [25], resulting in an under-
estimation of the burden of morning symptoms. Another
reason could be that patients with severe morning symptoms
are not willing to participate in studies that require visits to a
study center. Since the patients with morning symptoms are
probably missed in the studies requiring a morning visit, the
occurrence of morning symptoms is most likely underesti-
mated in those studies. Lastly, in some studies, physicians
scored the severity rate for the patients’ symptoms. Since
physicians do not pay considerable attention to morning
symptoms, they will probably underestimate the occurrence
of morning symptoms as well.
2.1. Symptoms in the morning
Several studies have described the prevalence of symptoms in
the morning [3,8,12,13,16,17,19–23,26,27]. Most frequently
occurring morning symptoms in all COPD patients were cough-
ing, shortness of breath, wheezing, and sputum production
[16,19,20,22,27] (Figure 2). In two studies, one that used a ‘phy-
sician completed patient record form’ to assess morning symp-
toms and one that did ‘symptom collection,’ the percentages for
cough, wheezing, and sputum were lower than in the previous
mentioned studies [21,28]. The symptom chest tightness was
common as well [16,20–22]. This symptom is more predominant
in the morning compared with other parts of the day [17].
In patients who experience morning symptoms, the most
common morning symptoms were coughing, shortness of
breath, and sputum production [3,12,13,23] (Figure 3).
Wheezing and chest tightness were common as well [17,23]
but were not examined in every study. In a study that included
only patients who experienced COPD symptoms affecting
typical morning routines, patients suffered from wheezing
(69%), chest tightness (63%), headache (35%), and exhaus-
tion/tiredness (at least 23%) [13]. In symptomatic patients,
37% experienced the morning the as worst time of the day.
The night is for symptomatic patients, the second worst part
of the day [3]. Symptomatic patients suffer mostly from cough,
dyspnea, and sputum production in the morning as opposed
to other parts of the day [8,17,26] (Figure 4).
Figure 1. Occurrence of morning symptoms in all COPD patients in different clinical studies.
COPD: chronic obstructive pulmonary disease
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Figure 2. Occurrence of different types of morning symptoms in COPD patients in different studies.
a) Percentage of all patients that suffer from dyspnoea in the morning. b) Percentage of all patients that suffer from cough in the morning. c) Percentage of all patients that
suffer from sputum production in the morning. d) Percentage of all patients that suffer from wheezing in the morning. COPD: Chronic obstructive pulmonary disease.
Figure 3. Occurrence of different types of morning symptoms in patients COPD with morning symptoms in different clinical studies.
a) Percentage of patients with morning symptoms that suffer from dyspnoea in the morning. b) Percentage of patients with morning symptoms that suffer from
cough in the morning. c) Percentage of patients with morning symptoms that suffer from sputum production in the morning. *Severe group. “Severe” was defined
in this study as: regular use of COPD medication plus a third level of breathlessness or above using Medical Research Council dyspnoea scale and one or more
exacerbations in the preceding 12 months. COPD: chronic obstructive pulmonary disease.
Figure 4. Occurrence of different types of morning symptoms in symptomatic COPD patients in different clinical studies.
a) Occurrence of dyspnoea in symptomatic COPD patients that mentioned the morning as most troublesome period of the day. b) Occurrence of cough in
symptomatic COPD patients that mentioned the morning as most troublesome period of the day. c) Occurrence of sputum production in symptomatic COPD
patients that mentioned the morning as most troublesome period of the day. COPD: chronic obstructive pulmonary disease
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2.2. Factors associated with morning symptoms
Multiple factors are associated with morning symptoms. These
factors include physical activity [29], nighttime symptoms
[20,23,24], poorer health status [21–24], current smoking
[3,21,23,24], an exacerbation in the previous 12 months
[21,24,30], more depression, and anxiety [20–23].
Furthermore, morning symptoms are associated with worsen-
ing of symptoms (that do not require a visit to a health-care
provider) [21] and more use of rescue medication [21,23,24].
But also, more primary care visits are associated with morning
symptoms [30]. The effects of modifying these factors on
morning symptoms have not been studied yet.
2.3. Conclusion
In conclusion, most COPD patients suffer from morning symp-
toms. The most common symptoms in the morning are dys-
pnea, cough, sputum, and wheezing. To get more insight in
the occurrence of morning symptoms, there is a need for a
clear definition of the morning. The pathophysiology of varia-
tion of symptoms of the day is unknown.
3. Tools to assess morning symptoms
In the recent years, morning symptoms in COPD have become
of more interest in research. The choice of the questionnaire
has a major influence on detected prevalence and severity
scores of morning symptoms. A validated morning symptoms
questionnaire is lacking; so, different tools and questionnaires
have been utilized. This chapter summarizes the used morning
symptom questionnaires. An overview is shown in Table 1.
Outcomes of the different questionnaires are reported in
Table 2.
3.1. Specific morning symptom questionnaires
In 2010, the ‘Capacity of Daily Living during the Morning
(CDLM)’ was developed [38]. This questionnaire was the first
morning symptom questionnaires. In the CDLM, patients
report their ability to carry out six different morning activities,
including washing themselves, drying themselves, dressing in
the morning, eating breakfast, and walking around the house
early and later in the morning. Patients are able to rank their
ability to carry out these morning activities from ‘not at all
difficult’ to ‘extremely difficult.’ The CDLM should be filled out
after completing all morning activities. The estimated mini-
mally important difference is 0.20. This questionnaire shows a
good-to-high reliability. Other tools that have been used to
assess morning symptoms in particular were the morning
assessment of the COPD eDiary [27], the ‘Patient-reported
outcome (PRO) Morning COPD symptoms Questionnaire’
[34], the ‘Manchester Early Morning, Symptoms Index
(MEMSI)’ [39], the ‘Early-Morning Symptoms of COPD
Instrument (EMSCI)’ [40], the ‘Morning Activity Questionnaire
(MAQ)’ [17], and the ‘chronic obstructive pulmonary disease
morning symptom diary’ (COPD-MSD) [13]. The morning
assessment of the COPD eDiary is a questionnaire that con-
tains five morning symptom items (‘shortness of breath,’
‘phlegm/mucus,’ ‘chest tightness,’ ‘wheezing,’ and ‘coughing’)
and two impact items (‘bothered by COPD’ and ‘difficulty with
activities’). Patients are able to rate all items from ‘none’ to
‘worst possible.’ The questionnaire must be completed
between waking up and before inhalation of medication. A
very high internal consistency for all seven diary items is
found. The PRO-Morning COPD symptoms Questionnaire is a
six-item questionnaire that was derived from the morning
assessment of the COPD eDiary. The MEMSI is a simple 10-
item one-dimensional questionnaire. During development,
COPD patients agreed that the five-option Likert-type scale
(‘never’ to ‘always’) was relevant and easy to understand. This
tool shows a good test reliability, test–retest repeatability, and
validity, but the minimal clinically important difference has not
been determined yet. The EMSCI assesses morning symptoms
(‘yes’ or ‘no’), the severity of these symptoms (‘mild’ to ‘very
severe’), and the impact of these symptoms (‘mild’ to ‘very
severe’). Patients should complete the questionnaire between
7 AM and 11 AM. This tool is still under validation. The MAQ
consists of one question about the impact of morning symp-
toms on morning activities in general. Patients are able to
score the impact from ‘minimal’ to ‘maximal.’ The most
recently developed questionnaire is the COPD-MSD [13]. For
the development of this questionnaire, COPD patients were
interviewed about their symptoms in the morning. The
phrases used in the questionnaire contain words that were
used by patients in the interviews, resulting in a questionnaire
that is understandable for patients. The COPD–MSD is still
under development, because it still contains too many items
and this tool has not been validated yet.
3.2. Questionnaires that included morning symptoms
There are also questionnaires that include morning symptoms
or can be used as morning symptom questionnaires because
they are suitable for each part of the day. The Global Chest
Symptoms Questionnaire (GCSQ) is a two-item questionnaire
developed to measure shortness of breath and chest symp-
toms at any part of the day (including the morning) [38].
Patients are able to rank their shortness of breath and chest
symptoms from ‘no symptoms at all’ to ‘extreme symptoms.’
This questionnaire shows a good-to-high reliability. Other
questionnaires that include morning symptom questions are
the ‘Night-time, Morning and Daytime Symptoms of COPD
questionnaire’ [20], the ‘Nighttime Symptoms Questionnaire’
[33], the ‘Clinical Symptom Questionnaire (CSQ)’ [17], and the
St. George’s Respiratory Questionnaire [41]. The ‘Night-time,
Morning and Daytime Symptoms of COPD questionnaire’ is a
33-item questionnaire about the prevalence, frequency, and
severity of COPD symptoms. Ten out of 33 questions are about
morning symptoms. Patients are asked about the frequency of
breathlessness, coughing, bringing up phlegm or mucus, chest
tightness, chest congestion, and wheezing during the period
from getting out of bed until 11 AM. Patients are able to rate
the severity of symptoms from ‘no symptoms’ to ‘very severe
symptoms.’ The questionnaire was linguistically validated. The
‘Nighttime Symptoms Questionnaire’ is an 11-item question-
naire that contains two questions about severity and impact of
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early morning symptoms. The patients should fill out this
questionnaire each morning in an electronic diary. The CSQ
is a self-reported questionnaire about clinical symptoms in
each part of the day. Patients are able to report in which
part of the day, their symptoms are most troublesome. They
are able to choose between ‘on waking,’ ‘in the morning,’ ‘in
the afternoon,’ ‘in the evening,’ or ‘at night.’ When patients
experience the morning as the worst part of the day, they can
also complete the MAQ. The MAQ was designed to give
insight in the impact of morning symptoms on morning activ-
ities since not every patient with symptoms in the morning
experiences an impact on morning activities.
One study reported an alternative way to identify severe
morning symptoms in COPD patients [24]. They stated that
the Clinical COPD Questionnaire (CCQ) [42] was also able to
identify patients with morning symptoms since patients with
severe morning symptoms had higher scores in CCQ and
these patients were not really missed when only measuring
the CCQ. One other study used the Asthma Control
Questionnaire [43], a questionnaire that has been developed
for asthma, to assess morning symptoms in COPD
patients [24].
3.3. Conclusions of tools to assess morning symptoms
In conclusion, at this moment, there is no standardized vali-
dated questionnaire to assess morning symptoms that is reg-
ularly used in clinical research. However, several
questionnaires have been developed and it is perceived that
for each new study, a novel morning symptom questionnaire
is utilized. Only the EMSCI and the GCSQ combined with the
CDLM were used in more than one study.
4. Therapy to limit morning symptoms
4.1. Pharmacotherapy
The effect of pharmacotherapy on morning symptoms has
been studied and is becoming of more interest in the recent
years. One study described that 79% of patients believed that
their medication provided sufficient relief of their morning
symptoms [12]. Fourteen percent of patients with morning
symptoms described that the use of any inhaled medication
reduced the severity of shortness of breath during morning
activities [13].
4.1.1. Bronchodilators
The basis of pharmacotherapy for COPD is bronchodilators [7].
However, the effect of long-acting beta2 agonists (LABAs) and
long-acting muscarinic antagonists (LAMAs) on morning
symptoms has only been assessed in a few studies. In recent
studies, frequent targets for treatment were the muscarinic
receptors because of the diurnal cholinergic effects on pul-
monary function. Most randomized controlled trials that stu-
died the effect of a LAMA on morning symptoms studied the
effect of aclidinium. Aclidinium twice daily reduced the pro-
portion of patients with at least moderate morning symptoms
[18,19,37]. Treatment with once-daily glycopyrronium [34] or
tiotropium [34,37] resulted in a decrease in morning symp-
toms (Table 3).
So far, aclidinium has been most extensively studied in this
context and treatment with aclidinium resulted not only in a
decrease of all morning symptoms, but also in a significant
improvement of the individual morning symptoms sputum
production, shortness of breath, wheezing, coughing, and
limitations of morning activities when compared with placebo.
There was a quantitatively greater improvement when com-
pared with tiotropium [37]. It could be speculated that the
positive effect of aclidinium could be due to the twice-daily
formula and the evening administration of the bronchodilator
that could lead to better nighttime bronchodilation and
potentially less symptoms in the morning. However, the
effects of a once-daily formula in the evening on morning
symptoms have not been adequately studied yet. In this con-
text, it also needs to be considered that the onset of acting of
different LAMAs could be a factor that may influence morning
symptoms [44]. In two studies, formoterol was added to acli-
dinium in two different fixed-dose combination [31,32]. In
both studies, combination therapy was more effective in
improving 24-h symptom control compared with placebo
[16], or the each component alone.
4.1.2. Bronchodilators combined with inhaled
corticosteroids
In the treatment of COPD, the effectiveness of inhaled corti-
costeroids (ICS) is controversial, but certain phenotypes of
COPD patients seem to benefit from ICS treatment [45]. The
effect of budesonide/formoterol combined with tiotropium
significantly improved morning symptoms predose as well as
5 and 15 min postdose as compared with tiotropium alone
[35]. In one other study, budesonide/formoterol was com-
pared with salmeterol/fluticasone [36]. This study showed no
significant difference in morning symptoms, but treatment
with budesonide/formoterol resulted in significant improve-
ment in the ability to perform tasks in the morning.
4.1.3. Important issues in medication studies
The positive effects of pharmacotherapy on morning symp-
toms are encouraging. Obviously, 17.9–40.1% of patients with
morning symptoms reported that they did not use inhaled
medication at baseline [16,24]. It is unclear whether the med-
ication was not prescribed or the patient did not use it.
However, it is remarkable that symptomatic patients did not
use medication. Previous research has shown that low treat-
ment adherence was associated with morning symptoms
[21,23], indicating that it is important to stimulate therapy
adherence to prevent morning symptoms. In one study, low
treatment adherence was defined as a score lower than six on
the Morisky Medication Adherence Scale [23]. The Morisky
Medication Adherence Scale [46] is a scale to assess adherence
to medication; the lower the score, the less is adherence. One
other study defined low treatment adherence as physician-
reported low treatment adherence [21]. In addition, one study
showed that most of the COPD patients do not adjust medica-
tion during a symptomatic period [8]. Patients take their med-
ication too late in the morning [3]. It is important to instruct to
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patients how and when they should use their medication as
this may reduce morning symptoms.
Notably, none of the interventional studies used morning
symptoms as primary end point but used pulmonary function
as primary end point. In these studies, pulmonary function
tests were performed before or just after the inhalation of
the morning dose. This resulted in the inclusion of more
patients with milder morning symptoms since patients with
severe morning symptoms will not be able to come to the
study center in the morning to perform a tough pulmonary
function test. This may have resulted in a smaller measured
treatment effect since the included patients already have less
morning symptoms.
4.2. Non-pharmacological therapy
Patients with morning symptoms were more likely to have
used oxygen in the past week than patients without morning
symptoms [23].To our knowledge, there are no studies per-
formed that evaluated the effect of conventional therapies,
such as physiotherapy, exercise training, cough therapy,
energy conservation techniques, nutrition, breathing techni-
ques, relaxing techniques, education and self-management,
integrated care programs, maintaining regular contact with
health-care providers, smoking cessation, social support, cog-
nitive therapy, and pulmonary rehabilitation on morning
symptoms. Although these therapies are well accepted in
the treatment of COPD patients [7], the effects on morning
symptoms are unknown.
4.3. Conclusion of therapy to limit morning symptoms
Pharmacotherapy has shown positive effects on morning
symptoms. Most intervention studies on morning symptoms
studied the effect of aclidinium. Hence, treatment with any
LAMA resulted in less morning symptoms [17,24]. However, in
all studies, morning symptoms were assessed with non-vali-
dated questionnaires. Medication adherence is important too
and low medication adherence is associated with morning
symptoms. For physicians, it is important to discuss medica-
tion adherence, the time of use of the inhaled medication and
inhalation technique should be checked.
5. Conclusion
Morning symptoms occur in the majority of COPD patients.
However, exact prevalence rates are unknown because a clear
definition of morning symptoms and a validated morning
symptom questionnaire are lacking. Despite the high fre-
quency of morning symptoms, there is barely attention for it
and this important topic is absent in current guidelines.
Pharmacotherapy seems to improve morning symptoms with
also significant effects on the ability to perform morning
activities. It seems to be important to control morning symp-
toms so as to provide a better start of the day. There seems to
be an important role for medication adherence and time of
medication use.
6. Expert commentary
In the past decade, morning symptoms in COPD have become
a focus in research. The amount of publications about morn-
ing symptoms and COPD is increasing. This is an important
evolution, because the prevalence of morning symptoms is a
substantial problem in COPD patients. We think that symp-
toms are becoming of more interest, because dyspnea is one
of the items in a simple multidimensional grading system to
predict the risk of death [47] and it is already implemented in
the GOLD classification [7]. Still, future research should give us
more information about the physiology and the impact of
morning symptoms on other well-respected outcomes such
as mortality and hospitalizations.
At this moment, a validated tool to assess morning symp-
toms is lacking. To study morning symptoms, a validated tool
is needed. We recommend a tool that includes symptoms,
severity of symptoms, and impact of the symptoms on activ-
ities. Also, a clear definition of the morning should be added. It
would also be useful to compare morning symptom question-
naires to identify which one covers morning symptoms the
best and which one is most patient friendly. This will result in a
standardized evaluation of morning symptoms, especially in
prospective studies with morning symptoms as primary end
point. In this way, we will be able to better understand why
morning symptoms occur, the impact of morning symptoms
and the underlying physiology. This can also result in new
targets for therapy.
Up till now, there is evidence that pharmacotherapy sig-
nificantly improves morning symptoms. However, some
patients are still uncontrolled despite using inhaled medica-
tion; so, further research is needed to fine-tune therapy. From
our view, future research should focus on medication in a
once-daily formula that is provided in the evening. This will
support the suggestions that an evening dose inhibits sputum
production during the night. Thereby, it should be evaluated
whether or not it will be better to prescribe patients with
morning symptoms a combination of LABA/LAMA and ICS.
Probably, patients with morning symptoms will profit more
from this combination because patients with morning symp-
toms have more frequent exacerbations. Recently, a review
concluded that some phenotypes with frequent exacerbations
require an ICS [48] and therefore, it could be possible that also
the morning symptom phenotype will profit from ICS therapy.
However, this hypothesis is so far not based on clinical data
and needs to be further studied. The development of fast-
acting inhaled medication has been a positive step in limiting
morning symptoms too. The effect of fast-acting medication
could result in a faster start up in the morning but more
research is warranted to show the effectiveness of this
approach. Thereby, physicians should keep in mind that they
don’t only prescribe the medication, but also make an indica-
tion of compliance. Physicians should stimulate and evaluate
adherence to therapy. Therapy adherence can be increased by
raising awareness with the patient of the disease and by
improving care cooperation [49] between different health-
care providers and patients [50]. To evaluate adherence, ques-
tionnaires can be filled out in the waiting room. Moreover,
e-health is upcoming in COPD and this will probably be a tool
320 A. R. VAN BUUL ET AL.
to increase awareness of the disease and may be a helpful tool
in detecting nonadherence.
Beside pharmacotherapy, we also expect that in further
research, different treatment approaches will be combined,
because in our opinion, pharmacotherapy alone will not
solve morning symptoms in all patients. For example, per-
sonalized treatment with inhaled medication combined
with cough instructions, exercise, breathing and relaxing
techniques, self-management, nutrition, oxygen therapy,
cognitive behavior therapy, smoking cessation, and/or pul-
monary rehabilitation. For future studies, it is also impor-
tant to include study visits in the afternoon. In most of the
present studies, it is not clear in which part of the day, the
pulmonary function tests were performed (most of the time
during ‘general care,’ so this can be any part of a working
day). In studies about morning symptoms, this is important
because patients with severe morning symptoms will not
decide to participate in a morning symptoms study because
they are not able to come in the morning. In future studies
assessing morning symptoms as primary end point, we
suggest that patients fill out questionnaires in the morning
at home and the time of the study visit could be in the
afternoon.
7. Five-year view
In conclusion, morning symptoms in COPD are an important
topic. However, the underlying pathophysiology is not yet well
understood. We expect that in 5 years due to further research,
the underlying pathophysiology and risk factors for morning
symptoms will become more clear. We expect that within
5 years, there will be a validated morning symptom question-
naire and more studies will have been done to investigate the
effect of pharmacotherapy, for example combinations of (fast-
acting) inhaled medication at different times of the day. We
also expect that the effect of non-pharmacological interven-
tions will be studied in morning symptoms. This will result in
evidence-based treatment plans to limit morning symptoms.
Including these plans in guidelines fit well in the upcoming
trend for personalized medicine. We strongly believe that
morning symptoms should be included in guidelines and
statements because we cannot ignore such an important
topic in COPD.
Key issues
● 39.9 to 94.4% of COPD patients are suffering from morning
symptoms.
● Most mentioned morning symptoms are dyspnoea, cough
and sputum production.
● Morning symptoms are not mentioned in COPD guide-
lines yet.
● There is no validated morning symptoms questionnaire
available yet. Such a questionnaire is needed to perform
structured future research.
● Morning symptoms seems to be a target for therapy.
● Pharmacotherapy can help to decrease morning symptoms
in COPD patients.
● Most intervention studies on morning symptoms studied
the effect of long-acting muscarinic antagonists.
● We strongly believe that morning symptoms should be
included into guidelines and statements.
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